Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

Table 1

Baseline patient characteristics.

Characteristics	Patients (𝑁=24)	Percent
	No.	(%)
Age, years
Median	60
Range	27–75
Sex
Male	2	8
Female	22	92
SWOG performance status
0	1	4
1	18	75
2	5	20
Histology
Leiomyosarcoma	24	100
Primary site
Uterus	11	46
Retroperitoneum	3	13
Other	10	42
Sites of metastases
Lung	15	63
Liver	14	58
Other	8	33
Prior treatment
Surgery	14	58
Radiotherapy	3	13
Chemotherapy	20	83
Doxorubicin	15	67
Dacarbazine	4	17
No. of prior chemo regimens
0	4	17
1	6	25
2	9	38
3	5	21